|
Pirfenidone Clinical Trials
2 actively recruiting trials across 1 location
▲ +1 trial since August 2026
Also known as: AiSiRui, PFD
Pipeline
Phase 2: 1Phase 1/2: 1
Top Sponsors
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology1
- National Institute of Allergy and Infectious Diseases (NIAID)1
Indications
- Combination of Fruquintinib and Anti-PD-1 Antibody Was Reported to Improve Patient Prognosis in Colorectal Cancer1
- To Evaluate Whether Pirfenidone Can Reshape the Tumor Microenvironment in Colorectal Cancer1
- To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma1
- Multiple Sclerosis1
- Cancer1
Other1 trial
Bethesda, Maryland1 trial
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
National Institutes of Health Clinical Center
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.